Company
Sydney, NSW
Every investor coverage indicates participated in a round Emergence 2026 raised.
Companies Emergence 2026 acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Emergence 2026. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Profile of Melbourne biotech Cartherics, which is extending its off-the-shelf cell therapy platform from ovarian cancer to endometriosis; its CEO outlines a capital raise in progress and 2026 clinical trial plans.
Profile of Snoretox, a biotech using a modified tetanus toxin to strengthen weak muscles in dogs and humans, which has won a $1 million government research grant and is seeking investors.